Delivered-To: oc.tjphuhs@gmail.com Received: by 2002:a05:6400:62d2:b0:2cf:4823:ed60 with SMTP id kw18csp929093ecb; Thu, 30 Apr 2026 08:00:51 -0700 (PDT) X-Received: by 2002:a05:690c:c50d:b0:79a:b1e1:49cd with SMTP id 00721157ae682-7bd5295eb44mr34506317b3.33.1777561250848; Thu, 30 Apr 2026 08:00:50 -0700 (PDT) ARC-Seal: i=1; a=rsa-sha256; t=1777561250; cv=none; d=google.com; s=arc-20240605; b=SqTQyL1wLdoYXWV6CaMnYRxCp67x1PAQJNxBWs3GBdtC5rSzcMCRYBIGvN/QgyxmEu vY4sg6pdKuIjLJs3V6DNui244eaVxTsIb0MuY247LuKmD7OevmfhAM9vc4gGZkA21wsS J3ufVJJe4zA3x8oDP1AtJIFQZfcgPrMR3CEAgOezVnKYEm8Jfiz/CCdYUGlE5PAh1LUB 6wjHMvO14nZPMgrCPITXMtTqGMDJ/T6VntrWkKmS1GV0sYIrpFCna/xfPgiTe+W8v3qX /0Syt5ObGBD/CPUW7Kb8vwRCBYIVbC6AGJ82xCujWzqVppjgXP3MhZjPSISRhSnO7zDV Q9lA== ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20240605; h=mime-version:subject:references:in-reply-to:message-id:to:from:date :dkim-signature; bh=7ke4xL7HY9B7Bk4x9Y9EmNB1KnvrO6WEVFBIsireLbE=; fh=F6Qtq/PC/9aW+A0Z/30DYnuZeFJIQSXKTJRrYsjMofs=; b=T1CaHb0HRxafjUwhqGmvBweHCei7D/dSRZZOOL2EfsR/DA5JMgeY3tI17E/+/gIdfO j7aHqHcX4mOAHpsDWZ8cNDkfeaAUk/MQlBqnJdaJ4rWnJ+pgQbj3x86/UPsjCNK3Vj+/ AbyQOzlNY8g/Dbpv3JaNXKscBk3LutKO9j46tSKORv1iLj00tm3YG/bBl1qm9qYydW47 kTcVuHbJV11Yuk6gngCyg++JNaJxAlAYygwZJzJNdrlSx2XfEvHUfQVXSkUlZ/kP3C3q QBbWWrqcCXaQ1tssAx757QLK9Vg6n/ROP4/oFJJkQSVh6qlFZUInqQjgrwo7wdWsIu4z Bp1Q==; dara=google.com ARC-Authentication-Results: i=1; mx.google.com; dkim=pass header.i=@gmail.com header.s=20251104 header.b=YktTFZgA; spf=pass (google.com: domain of tjphuhs@gmail.com designates 209.85.220.41 as permitted sender) smtp.mailfrom=tjphuhs@gmail.com; dmarc=pass (p=NONE sp=QUARANTINE dis=NONE) header.from=gmail.com; dara=pass header.i=@gmail.com Return-Path: Received: from mail-sor-f41.google.com (mail-sor-f41.google.com. [209.85.220.41]) by mx.google.com with SMTPS id 00721157ae682-7bd63e95287sor147527b3.10.2026.04.30.08.00.50 for (Google Transport Security); Thu, 30 Apr 2026 08:00:50 -0700 (PDT) Received-SPF: pass (google.com: domain of tjphuhs@gmail.com designates 209.85.220.41 as permitted sender) client-ip=209.85.220.41; Authentication-Results: mx.google.com; dkim=pass header.i=@gmail.com header.s=20251104 header.b=YktTFZgA; spf=pass (google.com: domain of tjphuhs@gmail.com designates 209.85.220.41 as permitted sender) smtp.mailfrom=tjphuhs@gmail.com; dmarc=pass (p=NONE sp=QUARANTINE dis=NONE) header.from=gmail.com; dara=pass header.i=@gmail.com DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=gmail.com; s=20251104; t=1777561250; x=1778166050; dara=google.com; h=mime-version:subject:references:in-reply-to:message-id:to:from:date :from:to:cc:subject:date:message-id:reply-to; bh=7ke4xL7HY9B7Bk4x9Y9EmNB1KnvrO6WEVFBIsireLbE=; b=YktTFZgAe8Cu3yYM9g6G24UX4S+lu9WeStAaBqVtN7kepfuiwZQ6XWU+IXrJfBdLJ4 7wJdK6mc2bRDmMuUgf9KIRH+XhBLzD9VBCG5rktcEvqsU3aXhClCqcoAcm7HfMVIG0v3 QUtWYU+S+bMdLz5xuTlOrgwUv85T+AO8bPnbJvxKfLWELGZYTmqYsXUOFVjNAc8VWzJ9 OgyTDXqmGYtz9sfFiU4cR44Vynvr3iiguxoLzT6lD7kXUQB2JS/xQXSIaKOw9AppJn73 Pp1Y+/7ALjZiWgH7Wzim8bOggcNeb6ArFaqzLYR3uIeD7NpP15zMZxGBzuhjdhj2HJP+ LM1A== X-Google-DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=1e100.net; s=20251104; t=1777561250; x=1778166050; h=mime-version:subject:references:in-reply-to:message-id:to:from:date :x-gm-gg:x-gm-message-state:from:to:cc:subject:date:message-id :reply-to; bh=7ke4xL7HY9B7Bk4x9Y9EmNB1KnvrO6WEVFBIsireLbE=; b=lg2mWDgPxfR+rFr1GQAieU3WRMRZei3ygvlHa1tPSi8Szg8a3pg0dRCsCyzYGSsH3b qNCDSdOWT8JWzg4aqm/jEyWWkGO8hc7UUolWOlWaKv8CNfzGVK1acaX61itoqMCQ/7VK fvGTehMmSiEwyqUyz8/BRHm/mI/oA5fYCWmGiwskA2/19hh+jFxUeQVbiXPN11nnxn2u s4ISCBdg1ROLagqcf3Mukd+nn2yiq2ese5Bj/wduDIRzccHvJ3j4x0PBOkuumJ8tgf5q xz7ZhIqKrhW2jBeZpCLq0RsSr2AuEDCci0xgjVZOGquYCAjIo0LlbD7Oyzb6HRPuLs2r rFKQ== X-Gm-Message-State: AOJu0YxBZgijVlM1Qvv4eWEtKQCz7zo0Dno05VYT+MuF9GcxG0tjqt3I 0jsh5QVEv7lHT78qguV8yrRFmP2swW5TvOFpqBEMqZKEk1m9MG0H1YlxVgQDfA== X-Gm-Gg: AeBDies9y5YknAKTd8woXAx6bIwp7y1gR34RCHoSTr/ifLEuyiLx4tbPeBtrYblZk7O ebFjQnUxSHQ9lOGYlxGYnD0dmfc+PDSjAfHfg4uC/Vs48PqkJKYNDXvQM9and5Z6tt7vWR5mLK2 Gi2Ige9t+1dWwsVaLu06sO/xfrm2toSaGDtrh0KZ+UfcZe9zxdKo6iSEnp9rtHB7xl2muva8RAY vI6nQn2+W7r4w/RCagCan/T2Dy+42zQbmVa2TOVAUqX6T1kqTGtjhEs1FI8qBf8F8DM2qi8BPyZ OsklLU4ydmIIkQO/RoADowbRzafa1P2M0l0rDGS+SMVTCEMWKxO/fCtflTors40Utts6sY8NHYJ X/VZtMuBKjZnmGaitMGBeevGGYxmqHYINgzOi1h481VBUfnmolOWNAHGMDmVxm7cOiQ4noJMb+j QK9MUhZltqqMd29qpCM2pu7jtBJadBm1l2EuhNjNHL+HZh+OrGDuMcRMTg0lL2RfJYqHrACbOO2 tsizA== X-Received: by 2002:a05:690c:6e83:b0:7b3:3a49:756 with SMTP id 00721157ae682-7bd5292bad5mr32622837b3.25.1777561247555; Thu, 30 Apr 2026 08:00:47 -0700 (PDT) Return-Path: Received: from [2607:fb90:e214:dabd::f0:ffff] ([2607:fb90:e214:dabd:d954:232b:bd27:ef56]) by smtp.gmail.com with ESMTPSA id 00721157ae682-7bd54b356d5sm10048967b3.11.2026.04.30.08.00.45 for (version=TLS1_2 cipher=ECDHE-ECDSA-AES128-GCM-SHA256 bits=128/128); Thu, 30 Apr 2026 08:00:47 -0700 (PDT) Date: Thu, 30 Apr 2026 11:00:22 -0400 From: tjphuhs@gmail.com To: "=?utf-8?Q?oc.tjphuhs=40gmail.com?=" Message-ID: <591e8c02-37b9-4282-9136-696a48d0cb87@Spark> In-Reply-To: <20260430141932.3.4d361568adcbcf41@mg-d0.substack.com> References: <20260430141932.3.4d361568adcbcf41@mg-d0.substack.com> Subject: Fwd: New Study Worth Knowing About: GLP-1s and Alzheimer's X-Readdle-Message-ID: 591e8c02-37b9-4282-9136-696a48d0cb87@Spark MIME-Version: 1.0 Content-Type: multipart/alternative; boundary="69f36e9a_2681724a_a8d8" --69f36e9a_2681724a_a8d8 Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: quoted-printable Content-Disposition: inline ---------- =46orwarded message ---------- =46rom: Derek from Research Radar Date: Apr 30, 2026 at 10:19=E2=80=AFAM -0400 To: tjphuhs=40gmail.com Subject: New Study Worth Knowing About: GLP-1s and Alzheimer's > A new research review just came out in Molecular and Cellular Neuroscie= nce (April 2026) looking at how GLP-1 drugs =E2=80=94 the same class as O= zempic, Wegovy, Mounjaro, and Trulicity =E2=80=94 might affect Alzheimer=E2= =80=99s disease. > =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0= =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2= =AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2= =A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87= =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F= =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80= =87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD= =8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2= =80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD= =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0= =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2= =AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2= =A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87= =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F= =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80= =87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD= =8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2= =80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD= =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0= =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2= =AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2= =A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87= =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F= =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80= =87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD= =8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2= =80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD= =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0= =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2= =AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2= =A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87= =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F= =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80= =87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD= =8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2= =80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD= =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0= =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2= =AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2= =A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87= =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F= =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80= =87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD= =8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2= =80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD= =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0= =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2= =AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2= =A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87= =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F= =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80= =87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD= =8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2= =80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD= =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0= =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2= =AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2= =A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87= =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F= =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80= =87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD= =8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2= =80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD= =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0= =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2= =AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2= =A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87= =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F= =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80= =87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD= =8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2= =80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD= =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0= =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2= =AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2= =A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87= =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F= =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80= =87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD= =8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2= =80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD= =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD > =46orwarded this email=3F Subscribe here for more > New Study Worth Knowing About: GLP-1s and Alzheimer's > Derek > Apr 30 > > READ IN APP > > A new research review just came out in Molecular and Cellular Neuroscie= nce (April 2026) looking at how GLP-1 drugs =E2=80=94 the same class as O= zempic, Wegovy, Mounjaro, and Trulicity =E2=80=94 might affect Alzheimer=E2= =80=99s disease. ScienceAlert covered it, but I wanted to dig into the ac= tual paper and break it down in plain English so anyone in the community = can follow along. > Link to the study: https://doi.org/10.1016/j.mcn.2026.104091 > ScienceAlert summary: https://www.sciencealert.com/weight-loss-drugs-ma= y-reduce-buildup-of-alzheimers-proteins-major-review-finds > Upgrade to paid > A Quick Primer on Alzheimer=E2=80=99s > Alzheimer=E2=80=99s is defined by two specific things going wrong in th= e brain: > > 1. > Amyloid-beta plaques =E2=80=94 sticky gunk that builds up between = your brain cells. Your body makes a protein called APP and chops it into = small pieces. In a healthy brain, those pieces get cleared out. In Alzhei= mer=E2=80=99s, they clump together into hard plaques that physically bloc= k neurons from communicating. > 2. > Tau tangles =E2=80=94 tau is a protein that lives inside your neur= ons and acts like the support beams holding the cell=E2=80=99s internal s= caffolding together. In Alzheimer=E2=80=99s, tau gets chemically gunked u= p (a process called =E2=80=9Chyperphosphorylation=E2=80=9D) and collapses= into twisted tangles inside the cell, which then dies. > > Plaques outside the cells, tangles inside the cells. Together they=E2=80= =99re considered the defining features of Alzheimer=E2=80=99s. Reduce eit= her one, and you=E2=80=99re theoretically slowing the disease. > The reason this matters for the study: GLP-1 drugs appear to reduce bot= h. > What The Researchers Did > A team out of Anglia Ruskin University in the UK did a systematic revie= w =E2=80=94 meaning they didn=E2=80=99t run a new experiment, they pulled= together every quality study they could find on four specific GLP-1 drug= s and looked for patterns: > > =E2=80=A2 > Liraglutide (Saxenda, Victoza) > =E2=80=A2 > Semaglutide (Ozempic, Wegovy) > =E2=80=A2 > Exenatide (Byetta, Bydureon) > =E2=80=A2 > Dulaglutide (Trulicity) > > They searched PubMed, Embase, and Cochrane Library =E2=80=94 the three = major medical research databases. They ended up with 30 preclinical studi= es (cells in a dish and animal models) and 2 human clinical trials. > The whole goal: do these drugs actually reduce amyloid plaques and tau = tangles=3F And if so, how=3F > What They =46ound in Animal and Cell Studies > This is where the data gets exciting: > > =E2=80=A2 > 22 out of 30 studies showed reductions in amyloid-beta plaq= ues > =E2=80=A2 > 19 out of 30 studies showed reductions in tau tangles > > That=E2=80=99s about 73% showing plaque reduction and 63% showing tangl= e reduction. In research terms, that=E2=80=99s a strong, consistent signa= l =E2=80=94 not a one-off finding. > By drug: > > =E2=80=A2 > Liraglutide =E2=80=94 the most studied of the four. The mos= t consistent. Reduced both plaques AND tangles across multiple models. > =E2=80=A2 > Dulaglutide =E2=80=94 fewer studies, but consistent. Reduce= d both plaques and tangles, and improved cognitive performance in mice. > =E2=80=A2 > Semaglutide =E2=80=94 mostly positive. =46our studies showe= d reductions, one showed no effect. > =E2=80=A2 > Exenatide =E2=80=94 most mixed results. Some studies showed= reductions, others showed nothing. Smallest overall effect. > > How Are GLP-1 Drugs Doing This=3F (The Mechanisms) > This is the most important section. The researchers identified several = pathways through which these drugs appear to fight Alzheimer=E2=80=99s pa= thology. Walking through them simply: > 1. They calm down brain inflammation > Your brain has its own immune cells called microglia. When microglia ge= t stuck in =E2=80=9Calarm mode=E2=80=9D for too long, they pump out infla= mmatory chemicals that actually increase the production of amyloid plaque= s. It=E2=80=99s a vicious cycle =E2=80=94 inflammation makes plaques, pla= ques cause more inflammation. > GLP-1 drugs calm microglia down. Less inflammation means less plaque pr= oduction at the source. > 2. They fix insulin signaling in the brain > There=E2=80=99s a reason researchers sometimes call Alzheimer=E2=80=99s= =E2=80=9CType 3 Diabetes.=E2=80=9D The Alzheimer=E2=80=99s brain shows i= nsulin resistance =E2=80=94 meaning brain cells can=E2=80=99t use sugar f= or energy properly. That metabolic dysfunction is directly tied to both p= laque buildup and tangle formation. > GLP-1 drugs were literally designed to fix insulin signaling. When they= restore that function in brain cells, the brain gets better at clearing = out toxic protein waste. > 3. They turn down the enzymes that make plaques > Remember APP =E2=80=94 the protein that gets chopped up into amyloid fr= agments=3F The enzymes doing the chopping are called secretases. GLP-1 dr= ugs appear to shift the balance away from the =E2=80=9Cbad=E2=80=9D cutti= ng pattern (which produces toxic plaque material) toward the =E2=80=9Csaf= e=E2=80=9D cutting pattern (which produces harmless fragments). > In other words, they reduce plaque production at the factory level. > 4. They block the enzyme that creates tangles > Tau gets converted into tangles by an enzyme called GSK-3=CE=B2. GLP-1 = drugs activate a signaling pathway (called PI3K/Akt) that inhibits GSK-3=CE= =B2. > Less GSK-3=CE=B2 activity =3D less tau gunking up =3D fewer tangles for= ming inside neurons. > 5. They help the brain clean itself out > Your brain has its own waste-clearance system that flushes out toxic pr= oteins. GLP-1 receptors are present on cells called astrocytes that sit a= round brain blood vessels. When activated, they help move water through t= he brain in a way that flushes amyloid out. > Imagine cleaning a room =E2=80=94 these drugs aren=E2=80=99t just stopp= ing the mess from getting made, they=E2=80=99re also helping take the tra= sh out. > 6. They help neurons survive in general > GLP-1 activation increases brain growth factors like BDN=46 (think of i= t as fertilizer for neurons), reduces oxidative stress, supports the cell= =E2=80=99s energy production, and prevents premature cell death. > This is the big-picture takeaway: these drugs aren=E2=80=99t doing one = thing. They=E2=80=99re doing six things at once, all in the same directio= n. That=E2=80=99s a big deal because most failed Alzheimer=E2=80=99s drug= s only targeted one mechanism. > The Human Trial Data =E2=80=94 Being Honest Here > This is where I have to slow the hype train down. The two human clinica= l trials in the review were not nearly as impressive as the animal data: > Liraglutide trial (26 weeks): > > =E2=80=A2 > No reduction in plaque burden > =E2=80=A2 > No improvement in cognition > =E2=80=A2 > Did preserve brain glucose metabolism (a sign neurons were = still functioning) > > Exenatide trial (18 months): > > =E2=80=A2 > No significant changes in plaques or tangles in cerebrospin= al fluid > =E2=80=A2 > Did reduce amyloid-beta in extracellular vesicles (an early= biomarker) > =E2=80=A2 > No cognitive benefit > > So: the preclinical data is strong. The human cognitive data is not the= re yet. > My Analysis =E2=80=94 What This Actually Means > A few honest takeaways: > 1. Preclinical-to-human translation is the eternal Alzheimer=E2=80=99s = problem. The graveyard of Alzheimer=E2=80=99s drug development is full of= compounds that worked beautifully in mice and failed in humans. Mouse mo= dels are typically genetically engineered to develop pathology fast =E2=80= =94 which doesn=E2=80=99t fully mirror what happens in a human brain over= decades. > 2. The lead author=E2=80=99s framing is the right one =E2=80=94 prevent= ion, not treatment. The researchers explicitly say these drugs may work a= s a preventative, not as a treatment for people who already have establis= hed cognitive impairment. That tracks with the human trial data =E2=80=94= those trials enrolled people who already had Alzheimer=E2=80=99s. By tha= t point, you may simply be too late. > 3. The multi-mechanism story is genuinely promising. Past Alzheimer=E2=80= =99s drugs failed because they targeted one pathway. GLP-1 drugs hit six = at once. That=E2=80=99s a structurally better bet. > 4. There=E2=80=99s a confounder nobody can fully solve yet. GLP-1 drugs= treat obesity and Type 2 diabetes =E2=80=94 two of the biggest modifiabl= e risk factors for dementia. So are these drugs protecting the brain dire= ctly, or are they protecting the brain by treating systemic metabolic dis= ease that would otherwise damage the brain=3F Probably both. The proporti= ons matter for figuring out who actually benefits most. > 5. This review only covers the older GLP-1 drugs. Tirzepatide (GLP-1 + = GIP) and retatrutide (GLP-1 + GIP + glucagon) aren=E2=80=99t in this anal= ysis. Whether the dual and triple agonists carry a similar =E2=80=94 or s= tronger =E2=80=94 neuroprotective signal is still an open question. > 6. The peptide research community has parallel tools worth knowing. Com= pounds like Cerebrolysin, Semax, Selank, and the bioregulators are workin= g on overlapping mechanisms (inflammation, neurotrophic support, neuronal= survival) through different pathways. The multi-mechanism neuroprotectio= n theme isn=E2=80=99t unique to GLP-1 drugs =E2=80=94 it=E2=80=99s where = the entire field is heading. > Bottom Line > This review pulls together strong preclinical evidence that GLP-1 recep= tor agonists reduce both amyloid plaques and tau tangles through multiple= mechanisms =E2=80=94 inflammation, insulin signaling, enzyme regulation,= brain clearance, and neuroprotection. The signal is consistent and biolo= gically coherent. > Human cognitive data isn=E2=80=99t there yet, but that=E2=80=99s likely= because the trials enrolled people too late in the disease. The next wav= e of trials needs to recruit at-risk people before symptoms start =E2=80=94= that=E2=80=99s where the real test happens. > This is one more data point worth tracking as the field develops. Stay = measured, watch the next 2-3 years of trial readouts, and don=E2=80=99t g= et ahead of the evidence. > Drop questions or thoughts below. > Disclaimer: This content is for research and educational purposes only = and is not medical advice. All compounds discussed (peptides, GLP-1 recep= tor agonists, and related research chemicals) are referenced in the conte= xt of research use only (RUO) and the published scientific literature. No= thing in this post should be interpreted as a recommendation for human co= nsumption, diagnosis, prevention, or treatment of any disease or conditio= n. Always consult a qualified healthcare professional for medical decisio= ns. > You're currently a free subscriber to Research Radar. =46or the full ex= perience, upgrade your subscription. > Upgrade to paid > > Share > > > Like > Comment > Restack > > =C2=A9 2026 Derek Pruski > 548 Market Street PMB 72296, San =46rancisco, CA 94104 > Unsubscribe --69f36e9a_2681724a_a8d8 Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable Content-Disposition: inline
---------- =46orwarded message ----= ------
=46rom: Derek from Research Radar <derekpruski=40substack.com&g= t;
Date: Apr 30, 2026 at 10:19=E2=80=AFAM -0400
To: tjphuhs=40gmail.com
Subject: New Study Worth Knowing About: GLP-1s and Alzheimer's

3D=22=22
A new research review just came out in Molecular and Cellular Ne= uroscience (April 2026) looking at how GLP-1 drugs =E2=80=94 the same cla= ss as Ozempic, Wegovy, Mounjaro, and Trulicity =E2=80=94 might affect Alz= heimer=E2=80=99s disease.
=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD
=46orwarded this email=3F Subscribe here for more=

New Study Worth Knowing About: GLP-1s and Alzheimer's

Derek
&=23160;=
3D=22=22=
3D=22=22=
3D=22=22
3D=22=22=
READ IN APP3D=
&=23160;=

A new research review just came ou= t in Molecular and Cellular Neuroscience (April 202= 6) looking at how GLP-1 drugs =E2=80=94 the same class as Ozempic, Wegovy= , Mounjaro, and Trulicity =E2=80=94 might affect Alzheimer=E2=80=99s dise= ase. ScienceAlert covered it, but I wanted to dig into the actual paper a= nd break it down in plain English so anyone in the community can follow a= long.

3D=22=22

Link to the study: https://doi.org/10= .1016/j.mcn.2026.104091

ScienceAlert summary: https://www.sc= iencealert.com/weight-loss-drugs-may-reduce-buildup-of-alzheimers-protein= s-major-review-finds

Upgrade to paid=

A Quick Primer on Alzheimer=E2=80= =99s

Alzheimer=E2=80=99s is defined by two specific things = going wrong in the brain:

  1. Amyloid-beta plaques =E2=80=94 sticky gunk that builds = up between your brain cells. Your body makes a prot= ein called APP and chops it into small pieces. In a healthy brain, those = pieces get cleared out. In Alzheimer=E2=80=99s, they clump together into = hard plaques that physically block neurons from communicating.

    =

  2. Tau tangles =E2=80=94 tau is a protein that lives inside your neurons and acts like the support beams hold= ing the cell=E2=80=99s internal scaffolding together. In Alzheimer=E2=80=99= s, tau gets chemically gunked up (a process called =E2=80=9Chyperphosphor= ylation=E2=80=9D) and collapses into twisted tangles inside the cell, whi= ch then dies.

Plaques outside the cells, tangles inside the cells. T= ogether they=E2=80=99re considered the defining features of Alzheimer=E2=80= =99s. Reduce either one, and you=E2=80=99re theoretically slowing the dis= ease.

The reason this matters for the study: GLP-1 dru= gs appear to reduce both.

What The Researchers Did

A team out of Anglia Ruskin University in the UK did a= systematic review =E2=80=94 meaning they didn=E2=80=99t run a new experi= ment, they pulled together every quality study they could find on four sp= ecific GLP-1 drugs and looked for patterns:

  • Liraglutide (Saxenda, Victoza)

  • Semaglutide (Ozempic, Wegovy)

  • Exenatide (Byetta, Bydureon)

  • Dulaglutide (Trulicity)

They searched PubMed, Embase, and Cochrane Libra= ry =E2=80=94 the three major medical research databases. They ended up wi= th 30 preclinical studies (cells in a dish = and animal models) and 2 human clinical trials.

The whole goal: do these drugs actually reduce amyloid= plaques and tau tangles=3F And if so, how=3F

What They =46ound in Animal and = Cell Studies

This is where the data gets exciting:

  • 22 out of 30 studies showed reductions in amyloid-beta = plaques

  • 19 out of 30 studies showed reductions in tau tangles

That=E2=80=99s about 73% showing plaque reduction and = 63% showing tangle reduction. In research terms, that=E2=80=99s a strong,= consistent signal =E2=80=94 not a one-off finding.

By drug:

  • Liraglutide =E2=80=94 the most studied of the four. The= most consistent. Reduced both plaques AND tangles across multiple models= .

  • Dulaglutide =E2=80=94 fewer studies, but consistent. Re= duced both plaques and tangles, and improved cognitive performance in mic= e.

  • Semaglutide =E2=80=94 mostly positive. =46our studies s= howed reductions, one showed no effect.

  • Exenatide =E2=80=94 most mixed results. Some studies sh= owed reductions, others showed nothing. Smallest overall effect.

How Are GLP-1 Drugs Doing This=3F= (The Mechanisms)

This is the most important section. The researchers id= entified several pathways through which these drugs appear to fight Alzhe= imer=E2=80=99s pathology. Walking through them simply:

1. They calm down brain inflamma= tion

Your brain has its own immune cells called micro= glia. When microglia get stuck in =E2=80=9Calarm mode=E2=80=9D for too lo= ng, they pump out inflammatory chemicals that actually increas= e the production of amyloid plaques. It=E2=80=99s a vicious cy= cle =E2=80=94 inflammation makes plaques, plaques cause more inflammation= .

GLP-1 drugs calm microglia down. Less inflammation mea= ns less plaque production at the source.

2. They fix insulin signaling in= the brain

There=E2=80=99s a reason researchers sometimes call Al= zheimer=E2=80=99s =E2=80=9CType 3 Diabetes.=E2=80=9D The Alzheimer=E2=80=99= s brain shows insulin resistance =E2=80=94 meaning brain cells can=E2=80=99= t use sugar for energy properly. That metabolic dysfunction is directly t= ied to both plaque buildup and tangle formation.

GLP-1 drugs were literally designed to fix insulin sig= naling. When they restore that function in brain cells, the brain gets be= tter at clearing out toxic protein waste.

3. They turn down the enzymes th= at make plaques

Remember APP =E2=80=94 the protein that gets chopped u= p into amyloid fragments=3F The enzymes doing the chopping are called sec= retases. GLP-1 drugs appear to shift the balance away from the =E2=80=9Cb= ad=E2=80=9D cutting pattern (which produces toxic plaque material) toward= the =E2=80=9Csafe=E2=80=9D cutting pattern (which produces harmless frag= ments).

In other words, they reduce plaque production at the f= actory level.

4. They block the enzyme that cr= eates tangles

Tau gets converted into tangles by an enzyme cal= led GSK-3=CE=B2. GLP-1 drugs activate a signaling pathway (called PI3K/Ak= t) that inhibits GSK-3=CE=B2.

Less GSK-3=CE=B2 activity =3D less tau gunking up =3D = fewer tangles forming inside neurons.

5. They help the brain clean its= elf out

Your brain has its own waste-clearance system that flu= shes out toxic proteins. GLP-1 receptors are present on cells called astr= ocytes that sit around brain blood vessels. When activated, they help mov= e water through the brain in a way that flushes amyloid out.

Imagine cleaning a room =E2=80=94 these drugs aren=E2=80= =99t just stopping the mess from getting made, they=E2=80=99re also helpi= ng take the trash out.

6. They help neurons survive in = general

GLP-1 activation increases brain growth factors like B= DN=46 (think of it as fertilizer for neurons), reduces oxidative stress, = supports the cell=E2=80=99s energy production, and prevents premature cel= l death.

This is the big-picture takeaway: these drugs aren=E2=80=99t doing one thing. They=E2=80=99re doing six th= ings at once, all in the same direction. That=E2=80=99s a = big deal because most failed Alzheimer=E2=80=99s drugs only targeted one = mechanism.

The Human Trial Data =E2=80=94 B= eing Honest Here

This is where I have to slow the hype train down= . The two human clinical trials in the review were not nearly as impressive as the animal data:

Liraglutide trial (26 weeks):

  • No re= duction in plaque burden

  • No im= provement in cognition

  • Did p= reserve brain glucose metabolism (a sign neurons were still functioning)<= /p>

Exenatide trial (18 months):

  • No si= gnificant changes in plaques or tangles in cerebrospinal fluid

  • Did r= educe amyloid-beta in extracellular vesicles (an early biomarker)

  • No co= gnitive benefit

So: the preclinical data is stron= g. The human cognitive data is not there yet.

My Analysis =E2=80=94 What This = Actually Means

A few honest takeaways:

1. Preclinical-to-human translation is the ete= rnal Alzheimer=E2=80=99s problem. The graveyard of Alzheim= er=E2=80=99s drug development is full of compounds that worked beautifull= y in mice and failed in humans. Mouse models are typically genetically en= gineered to develop pathology fast =E2=80=94 which doesn=E2=80=99t fully = mirror what happens in a human brain over decades.

2. The lead author=E2=80=99s framing is the ri= ght one =E2=80=94 prevention, not treatment. The researche= rs explicitly say these drugs may work as a preventative<= span>, not as a treatment for people who already have established cogniti= ve impairment. That tracks with the human trial data =E2=80=94 those tria= ls enrolled people who already had Alzheimer=E2=80=99s. By that point, yo= u may simply be too late.

3. The multi-mechanism story is genuinely prom= ising. Past Alzheimer=E2=80=99s drugs failed because they = targeted one pathway. GLP-1 drugs hit six at once. That=E2=80=99s a struc= turally better bet.

4. There=E2=80=99s a confounder nobody can ful= ly solve yet. GLP-1 drugs treat obesity and Type 2 diabete= s =E2=80=94 two of the biggest modifiable risk factors for dementia. So a= re these drugs protecting the brain directly, or ar= e they protecting the brain by treating systemic metabolic disease that w= ould otherwise damage the brain=3F Probably both. The proportions matter = for figuring out who actually benefits most.

5. This review only covers the older GLP-1 dru= gs. Tirzepatide (GLP-1 + GIP) and retatrutide (GLP-1 + GIP= + glucagon) aren=E2=80=99t in this analysis. Whether the dual and triple= agonists carry a similar =E2=80=94 or stronger =E2=80=94 neuroprotective= signal is still an open question.

6. The peptide research community has parallel= tools worth knowing. Compounds like Cerebrolysin, Semax, = Selank, and the bioregulators are working on overlapping mechanisms (infl= ammation, neurotrophic support, neuronal survival) through different path= ways. The multi-mechanism neuroprotection theme isn=E2=80=99t unique to G= LP-1 drugs =E2=80=94 it=E2=80=99s where the entire field is heading.

Bottom Line

This review pulls together strong preclinical evidence= that GLP-1 receptor agonists reduce both amyloid plaques and tau tangles= through multiple mechanisms =E2=80=94 inflammation, insulin signaling, e= nzyme regulation, brain clearance, and neuroprotection. The signal is con= sistent and biologically coherent.

Human cognitive data isn=E2=80=99t there yet, but that= =E2=80=99s likely because the trials enrolled people too late in the dise= ase. The next wave of trials needs to recruit at-risk people before sympt= oms start =E2=80=94 that=E2=80=99s where the real test happens.

This is one more data point worth tracking as the fiel= d develops. Stay measured, watch the next 2-3 years of trial readouts, an= d don=E2=80=99t get ahead of the evidence.

Drop questions or thoughts below.

Disclaimer: This content is for r= esearch and educational purposes only and is not medical advice. All comp= ounds discussed (peptides, GLP-1 receptor agonists, and related research = chemicals) are referenced in the context of research use only (RUO) and t= he published scientific literature. Nothing in this post should be interp= reted as a recommendation for human consumption, diagnosis, prevention, o= r treatment of any disease or condition. Always consult a qualified healt= hcare professional for medical decisions.

You're= currently a free subscriber to Research Radar. =46or the full experience, upgrade your subscription.

Upgra= de to paid

&=23160;=
3D=22=22Share
&=23160;=
&=23160;=
3D=22=Like
3D=22=22=Comment
Restack
&=23160;=

=C2=A9 2026 Derek Pruski
548 Market Street PMB 72296, San =46rancisco, CA 94104
Unsubscribe

3D=22Start
3D=22=22
--69f36e9a_2681724a_a8d8--